the impact of orlistat on diabetic patients experiencing overweight and constipation: a randomized clinical trial

Objective: obesity is a global health concern, the use of orlistat as an anti-obesity drug, has shown promise in managing the constipation and blood sugar levels in diabetic patients. this study aimed to evaluate the impact of orlistat on diabetic patients experiencing both overweight and constipation.materials and methods: a total of 80 overweight and constipated diabetic patients were randomly enrolled. participants were randomly assigned to either the intervention or control group. the intervention group received 120 mg orlistat with lunch for three months, while the control group received placebo, taken once daily with lunch for the same duration. clinical and paraclinical parameters, including body mass index (bmi), constipation, fasting blood sugar (fbs), hba1c, triglycerides (tg), cholesterol (chl), high-density lipoprotein (hdl), creatinine (cr), aspartate transaminase (ast), alanine transaminase (alt), and blood sugar two hours postprandial (bs-2hpp), were assessed before and after the intervention.results: significantly, the bs-2hpp and alt decreased in the interventiom group. additionally, there was a noteworthy improvement in constipation within the intervention group compared to the control group.conclusion: orlistat demonstrates some effectiveness in improving clinical parameters in diabetic patients with obesity and constipation. while the drug shows notable efficacy in alleviating constipation, its impact on other related parameters is not statistically significant. no significant side effects were observed with orlistat.